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Informatics in Medicine, University Rostock, Germany.BACKGROUND The incidence of atrial ﬁbrillation (AF) after
ablation of a cavotricuspid isthmus (CTI)–dependent atrial ﬂutter
(AFL) is high.
OBJECTIVE The purpose of this study was to test the hypothesis
that AFL and AF may be initiated by pulmonary vein triggers. This
prospective randomized trial tested the efﬁcacy of a standalone
pulmonary vein isolation (PVI) in patients with AFL but without AF.
METHODS Patients with AFL but without documented AF were
randomly assigned to 1 of 3 treatment groups: (1) antiarrhythmic
drugs (AAD), (2) CTI ablation, or (3) circumferential PVI. The
primary end-point was deﬁned as any recurrent atrial tachyar-
rhythmia and the secondary end-point as recurrence of AFL. In case
of tachyarrhythmia recurrence in the PVI group, a second PVI was
performed to close gaps in the ablation lines.
RESULTS Of the 60 patients, 17 were randomized to AAD, 23 to CTI
ablation, and 20 to PVI. During follow-up of 1.42  0.83 years, 14
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reached the primary end-point (P o.001) after a mean of 1.4 PVI
procedures per patient. AFL reoccurred in 9 patients (52.9.%) in the
AAD group, in 2 patients (8.7%) in the CTI group, and after a single
PVI in 3 patients (15%) in the PVI group (P¼ .003). After closure of
gaps, 1 patient (5%) in the PVI group presented with recurrent AFL.
CONCLUSION Pulmonary vein triggers play an important role in AFL.
PVI can prevent the recurrence of AFL, even without CTI ablation.
KEYWORDS Atrial ﬁbrillation; Atrial ﬂutter; Radiofrequency
ablation; Three-dimensional electroanatomic reconstruction
ABBREVIATIONS AAD ¼ antiarrhythmic drug; AF ¼ atrial
ﬁbrillation; AFL ¼ atrial ﬂutter; CTI ¼ cavotricuspid isthmus;
ECG¼ electrocardiography; ILR ¼ implantable loop recorder; PV¼
pulmonary vein; PVI ¼ pulmonary vein isolation
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Ablation of the cavotricuspid isthmus (CTI) is the therapy of
choice for treatment of typical atrial ﬂutter (AFL).1,2
However, many patients also present with atrial ﬁbrillation
(AF) at the time of ablation or during follow-up.3–7 In
patients with isolated AFL and no documentation of other
arrhythmias, the incidence of AF was 12.9% 6 months after
CTI ablation5 and increased progressively to 50% after 2.5years6 and 82% after 39 months.7 In patients with preexist-
ing AF, the incidence was even higher than in patients with
isolated AFL.8,9 A close pathophysiologic interrelationship
between both arrhythmias has been suggested for many
years10,11 and is backed by current clinical and experimental
studies.12 These studies raise the question whether both
arrhythmias are initiated by the same electrical trigger.10,12
AF is mainly initiated by triggers from the pulmonary veins
(PVs),13 and recent studies demonstrated the beneﬁt of an
additional pulmonary vein isolation (PVI) in patients with
isolated AFL.14,15
The aim of this study was to examine the efﬁcacy of a
standalone PVI in patients with AFL but without AF. We
report the initial results of the ongoing prospective
randomized Atrial Fibrillation Ablation in Atrial Flutter
(Triple A) study.http://dx.doi.org/10.1016/j.hrthm.2015.01.040
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Patients
The study was approved by the local Ethics Board of the
University of Rostock. Consecutive patients with docu-
mented typical right AFL on surface 12-lead electrocardio-
gram (ECG) referred to our hospital between August 2010
and October 2013 were enrolled into the study. Careful
evaluations of previous ECGs were performed. Patients with
a history of AF or previous CTI ablation at the time of
enrollment were excluded.
Other exclusion criteria were AV nodal reentrant tachy-
cardia, accessory pathways, left atrial dilation 46 cm,
previous valve surgery, and congenital heart disease.
Efforts were made to induce AFL during electrophysio-
logic study. Noninducibility was not an exclusion criterion in
this trial because conditions promoting the transition to AFL
may be present only temporarily.16–19Study design
Patients were randomly assigned to 1 of the following
groups: (1) antiarrhythmic drug (AAD) therapy, (2) ablation
of the CTI, or (3) standalone circumferential PVI without
additional trigger ablation or substrate modiﬁcation. All
patients gave written informed consent for the study and
procedure.
Patients randomized to AAD were treated for up to 6
months. Class IC AADs were prescribed in patients without,
and amiodarone in patients with, structural heart disease. If
patients presented with AFL at time of randomization,
electrical cardioversion was performed. Patients randomized
to the CTI or PVI group underwent electrophysiologic study
under sedation with continuous infusion of propofol. If
patients were in AFL, entrainment was performed from the
CTI to conﬁrm AFL.
Transseptal puncture was performed in all ablation
patients with the intention to induce AFL from the PVs.
After transseptal puncture, intravenous heparin was admin-
istered to maintain an activated clotting time of 250 to 350
seconds. A circular mapping catheter (Lasso, Biosense
Webster, Diamond Bar, CA) was positioned via an SL-1
sheath (8Fr or 8.5Fr, St. Jude Medical, St. Paul, MN) in the
left superior PV, and repetitive burst pacing up to 30 seconds
was performed. To avoid immediate initiation of AF, pacing
was started well above the documented clinical AFL cycle
length. The initial burst pacing cycle length of 350 ms was
decreased by 10 ms every second down to 250 ms and if
necessary every 2 to 3 seconds thereafter. The delay in CTI
conduction was monitored. If 1:1 left-to-right atrial con-
duction was lost, pacing was terminated and reinitiated
slightly above this cycle length. If AF was induced, pacing
was immediately terminated and conversion to AFL was
awaited for several minutes. If progression did not occur,
AADs (up to 100 mg ﬂecainide or 300 mg amiodarone) were
administered intravenously to support conversion of AF into
AFL. If AF persisted, cardioversion was performed before
ablation.In the CTI group, the transseptal sheath was retracted and
irrigated radiofrequency ablation of the CTI was performed
(Celsius, Biosense Webster) with power up to 50 W, ﬂow
rate up to 30 mL/min, and temperature limit of 43ºC.
Bidirectional conduction block was deﬁned as the end-
point of CTI ablation.
In the PVI group, PVI was performed as previously
described.20 The end-point of wide circumferential PV
ablation was deﬁned as absence of any PV spike within the
ipsilateral PVs. Exit block of the left-sided veins was tested
to differentiate left atrial appendage signals from residual PV
signals.
Because gaps in the ablation lines after PVI are frequent, a
second procedure to close these gaps was considered an
integral part of the ablation if arrhythmias recurred.20 The
second ablation was not performed until a minimum time
interval of 3 months elapsed from the ﬁrst procedure.
Monitoring of arrhythmias
Implantation of an implantable loop recorder (ILR; Reveal
XT, Medtronic, Inc, Minneapolis, MN, USA) was offered to
all patients to capture even asymptomatic arrhythmias.21–23
All stored electrograms were carefully evaluated to avoid
misclassiﬁcation of AF.21,22 If patients refused loop recorder
implantation, a 7-day Holter ECG was performed 3 and 6
months after randomization and every 6 months thereafter.
AF lasting more than 30 seconds and all AFL episodes were
documented without blanking period because early recur-
rence of AF predicts late recurrence.24,25
Postablation procedure
After ablation, patients were transferred to the intermediate
care unit. Oral anticoagulation was continued after exclusion
of pericardial effusion on the day following the ablation
procedure.
Study end-points
The primary end-point of the study was deﬁned as occur-
rence of any arrhythmias during follow-up and the secondary
end-point as occurrence of AFL after randomization. The
starting time point of this analysis was the time of the initial
procedure (AAD, CTI ablation, PVI).
Statistical analysis
The sample size was determined using the computer software
nQuery Advisor 7.0. For the type I error α = 0.05 (2-sided), a
power of 1-β = 0.80 and the expected reduction of
arrhythmia recurrence after follow-up of 3 years from
100% (AAD group) to 60% (CTI group) and 30% (PVI
group) were calculated; patient recruitment was set for 50
patients per group. Calculation was realized by using module
PTT2-1 in nQuery for a 2-group Fisher exact test of equal
proportions because of the most important question regard-
ing a relevant difference between the CTI and PVI groups.
For a global comparison between the 3 groups (100% vs
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module PGT0-2 [χ2 test of equal proportions in 3 groups]).
After enrollment of 60 patients, a prespeciﬁed interim
analysis was performed in order to stop the trial in case the
outcome of the PVI group was unfavorable.
All data were stored and analyzed using the Windows-
based statistical software SPSS (version 21, IBM SPSS
Statistics, Inc, Chicago, IL, USA). Descriptive statistics were
computed for continuous and categorical variables. All
continuous variables are presented as mean  SD. Catego-
rical variables are presented as frequency and percentage.
Testing for differences of continuous variables between the 3
study groups, created by therapy, was accomplished by
1-way analysis of variance or the Kruskal–Wallis test, as
appropriate. For signiﬁcant differences post hoc least sig-
niﬁcance difference tests or Mann–Whitney U tests were
used to compare 2 groups in each case. Test selection was
based on evaluating the variables for normal distribution
using the Kolmogorov–Smirnov test.
For categorical variables, comparisons were made using
the χ2 test or Fisher exact test. Period of time until AF
occurred or time until last observation was analyzed using
the Kaplan–Meier method. Between-group differences were
assessed by the Mantel log rank test for censored survival
data. All P values resulting from 2-sided statistical tests and
P o.05 were considered signiﬁcant.
Results
Patients
A total of 60 patients (48 men [80%]) were included in the
study at the time of the prespeciﬁed interim analysis. Of
these patients, 17 (28.3%) were randomized to AAD therapy,
23 (38.3%) to CTI ablation, and 20 (33.3%) to PVI alone. All
groups were well balanced; baseline characteristics are given
in Table 1. A mean time of 6.7  14.5 months elapsed




Age (years) 62.3  8
Spontaneous atrial ﬂutter cycle length (ms) 229  2
Hypertension [n (%)] 51 (85)
Diabetes mellitus 21 (35)
Structural heart disease 23 (38.
Revascularization 14 (23.
Ejection fraction (%) 54.8  1
Left atrial diameter (mm) 44.7  7
Implanted rhythm device (%) 48 (80)
Follow-up (years) 1.42  0
Follow-up after successful ﬁrst ablation or after closure of
gaps in second ablation (years)
Values are given as no. (%) or mean  SD unless otherwise indicated.
AAD ¼ antiarrhythmic drug; CTI ¼ cavotricuspid isthmus; PVI ¼ pulmonary v
*χ2 test.
†Kruskal–Wallis test.
‡Mann–Whitney U test.Enrollment and electrophysiologic data
At the time of randomization, 26 patients had persistent AFL.
Eight patients were randomized to the AAD group and were
successfully cardioverted. At the time of electrophysiologic
study, 4 patients (17.4%) in the CTI group had persistent
AFL, and AFL was inducible in 16 patients (69.6%); 2
patients (10%) in the PVI group had persistent AFL, and
AFL was inducible in 11 patients (55%, P ¼ .669). AF was
inducible in 1 patient in the CTI group and in 5 patients in the
PVI group (P¼ .081). All episodes of induced AF/AFL were
initiated by burst pacing. Electrophysiologic data are sum-
marized in Table 2. In 23 of 27 patients (85.2%), AFL was
induced by burst pacing from the left superior PV and in the
remaining 4 patients from the distal coronary sinus. An
episode of AF preceded induced episodes of AFL in 12
patients (44.4%; 8 in the CTI group and 4 in the PVI group).
Clockwise AFL was induced in only 1 patient. AADs were
used to convert AF to AFL in 7 patients. The cycle length of
induced AFL was signiﬁcantly longer than the cycle length
of spontaneous AFL (P o.001).
The primary end-point of bidirectional conduction block
of the CTI (CTI group) or PVI (PVI group) was achieved in
all patients.Postprocedural monitoring
Forty-eight patients (80%) received or had a device for
arrhythmia monitoring (45 ILR, 2 pacemaker, 1 ICD). In 2
other patients, the ILR was explanted. In these 2 patients and
the remaining 10 patients (3 AAD, 4 CTI, 3 PVI) follow-up
was completed with 7-day Holter ECG.Complications
One patient had a pericardial effusion after the second PVI
that needed drainage. In 1 AAD patient the ILR was
explanted because of conﬁrmed infection. Atriovenousts AAD group CTI group PVI group P value
17 23 20
12 (70.6) 21 (91.3) 15 (75%) .213*
.8 61.7  8.7 63.9  7.9 61.1  10 .517†
8 236  36 226  27 226  19 .590†
13 (76.5) 21 (91.3) 17 (85) .430*
5 (29.4) 10 (43.5) 6 (30) .554*
3) 6 (35.3) 8 (34.8) 9 (45) .754*
3) 4 (23.5) 5 (21.7) 5 (25) .968*
2.1 55.1  11.4 55.5  11.5 53.7  13.6 .924†
.2 44.8  8.1 43.2  6.7 46.1  7.0 .504†
12 (70.6) 19 (82.6) 17 (85) .509*
.83 1.50  0.75 1.39  0.81 1.40  0.94 .871†
1.35  0.79 1.03  0.88 .177‡
ein isolation.
Table 2 Electrophysiologic data of the ablation groups
CTI group PVI group P value†
AFL at EPS [n (%)] 20 (87) 13 (65) .148†
Induced AFL [n (%)] 16 (69.6) 11 (55) .361†
Induced AFL cycle length at EPS (ms) (mean  SD) 262  32 279  73 .671*
Antecedent AF at EPS induction [n (%)] 8 (34.8) 4 (20) .327†
Only AF inducible [n (%)] 1 (4.3) 5 (25) .081†
Ablation in AFL [n (%)] 12 (60) 0 (0) o.001†




Figure 1 Kaplan–Meier curve for the primary end-point, including a
second ablation (A) and after a single ablation procedure (B). AAD ¼
antiarrhythmic drug; CTI ¼ cavotricuspid isthmus; PVI ¼ pulmonary vein
isolation.
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occurred in 2 patients (1 after coronary angiography).
Outcome
After mean follow-up of 1.42 0.83 years, 14 of 17 patients
(82.4%) reached the primary end-point in the AAD group, 14
of 23 patients (60.9%) in the CTI group, and 2 of 20 patients
(10%) in the PVI group after a mean of 1.4 PVI procedures
per patient (Figure 1A; χ2 test, Po.001; log rank test overall
0.001, log rank test for AAD vs CTI P ¼ .216, for AAD vs
PVI P o.001, for CTI vs PVI P ¼ .005). However, after a
single PVI procedure, 8 of 20 patients (40%) developed atrial
tachyarrhythmias (87.5% at least 1 episode of AF); there was
no signiﬁcant difference between the 3 groups after a single
PVI (Figure 1B; log rank test overall P ¼ .144, for AAD vs
CTI P¼ .26, for AAD vs PVI P¼ .067, for CTI vs PVI P¼
.294). Early recurrences during the ﬁrst 3 months after
ablation were noted in 5 of 8 PVI patients. All experienced
late recurrences. In the CTI group, 7 of 14 patients had new-
onset AF during the ﬁrst 3 months after ablation, and all
experienced late recurrences of AF.
In the AAD group with arrhythmia recurrences, 7 patients
had only AFL, 5 had only AF, and 2 had AF that organized
intermittently to AFL. There was no difference in arrhythmia
detection between patients with Holter or ILR (χ2 test,
P ¼ .598).
The secondary end-point (recurrence of AFL) was
reached in 9 patients (52.9%) in the AAD group, and after
a single ablation procedure in 2 patients (8.7%) in the CTI
group and in 3 patients (15%) in the PVI group (χ2 test, P ¼
.003; log rank test overall P ¼ .005, for AAD vs CTI P ¼
.005, for AAD vs PVI P ¼ .034).
Of 8 patients with recurrent arrhythmias after PVI, 7 had
at least 1 gap in the circumferential PV lines during a second
PVI procedure. Including this second ablation, only 1 patient
in the PVI group reached the secondary end-point (Figure 2).
There was no signiﬁcant difference concerning the secon-
dary end-point between the CTI and PVI groups after closing
the gaps in the initial ablation lines (log rank test P ¼ .226).
Patients in the PVI and CTI groups experienced recurrences
of AFL less frequently than did patients in the AAD group
(log rank test P o.001 for CTI and P ¼ .008 for PVI).
Both patients with reablation of the CTI experienced AF
during follow-up. In 1 patient with recurrent AFL after asecond PVI, a third procedure revealed a remaining gap in
the ablation line around the left-sided veins. After closure of
this gap the patient remained free of any arrhythmia for 12
months. In the other patient with AF recurrence, the PVs
were isolated but a variety of extra-PV triggers were noted
during both procedures.
Figure 2 Kaplan–Meier curve for the secondary end-point, including a
second cavotricuspid isthmus (CTI) or pulmonary vein isolation (PVI)
procedure (A) and after a single procedure (B). The antiarrhythmic drug
(AAD) group is shown for comparison.
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after the index procedure experienced episodes of AF
organizing to AFL, except for 1 patient in the PVI group.
In the AAD group, 7 patients (41.2%) with a recurrent
arrhythmia experienced at least 1 short episode of AF. All




We report the initial results of an ongoing single-center
randomized trial with different treatment strategies in
patients with isolated AFL. All patients had no history of
AF and no documented AF at the time of ﬁrst clinical
presentation. Patients were assigned to 1 of 3 treatment arms.
We found that PVI can prevent the recurrence of AFL even
without CTI ablation. A completion of PVI with repetitive
procedures was a prerequisite of arrhythmia suppression in
some patients. The assumption that a PVI was mandatory toprevent AFL recurrence is supported by the observation that
1 patient with AFL recurrence after the second PVI still
needed closure of a gap during a third procedure. However,
we did not assess PV reconnections in patients without
arrhythmia recurrence. Thus, it is possible that some of these
patients, if studied, would have reconnections even though
they did not have clinical arrhythmia recurrence.
Although CTI ablation has proved to be superior to drug
therapy for treatment of AFL,2 we included an AAD group in
order to investigate the prevalence of AF in these patients
with an intensiﬁed monitoring. In previous studies, the term
isolated Aﬂut was derived from the medical record data-
bases, and an intensiﬁed preablation monitoring has never
been reported in patients with isolated AFL.5–7 Our results
conﬁrm the additional existence of AF in many patients with
supposed “isolated” AFL.
Interestingly, there was a cycle length difference between
documented AFL and cycle length at electrophysiologic
study. This may be attributed to a combination of rough
estimation from surface ECG of clinical AFL as well as
sedation and use of AADs during electrophysiologic study.
Pathophysiologic implications
AF is often a coexisting arrhythmia in patients with
AFL.26,27 The question has been raised whether AFL is a
potential trigger for AF or AF is the underlying clinical
arrhythmia for AFL.10 Our results strongly suggest that for
the initiation of both arrhythmias, the PVs play an important
role. Accordingly, PVI can prevent AF and AFL. This is in
line with results from other studies.26,27
Although our patients did not show a history of AF at the
time of enrollment, 41.2% of patients in the AAD group,
60.9% in the CTI group, and 35% in the PVI group after a
single ablation procedure had AF during follow-up. With the
exception of 1 patient who had a variety of extra-PV triggers,
all patients who had new documented AF after the ﬁrst PVI
had at least 1 gap in the circumferential lines. After closure of
all gaps in a second PVI procedure, freedom from AF
increased to 90% and freedom from AFL to 95% during
follow-up of 1.03  0.88 years.
In our series, the 2 patients with AFL recurrence in the
CTI group showed recurrent CTI conduction. After closing
this gap, they continued to develop paroxysmal AF. It seems
reasonable to assume that after CTI ablation AF wavefronts
cannot “reorganize” to stable AFL, leading to either AF
persistence or termination to sinus rhythm.
Clinical implications
Several clinical trials assessed the relationship between AFL
and AF.7,15,26 Ellis et al7 reported a high incidence of AF (up
to 82%) after CTI ablation in patients with isolated AFL
during mean follow-up time of 39 months. Wazni et al26
demonstrated that in patients with both AF and AFL, PVI is
sufﬁcient to control both arrhythmias, although in the
blanking period 55% of patients still had episodes of typical
AFL and some patients had antiarrhythmic therapy or
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another study.27 In contrast to these 2 studies, our patients
did not show a history of AF, and we were able to
demonstrate that even in the absence of documented AF
the PVs play an important role in the initiation of AFL and
that PVI is sufﬁcient to control AF and AFL without
antiarrhythmic therapy. Our study conﬁrmed the beneﬁt of
additional PVI in patients without documented AF as shown
by Navarrete et al.15 They demonstrated that in patients with
isolated AFL and no history of AF, a combination of CTI
ablation and PVI reduced the rate of any tachyarrhythmias
during follow-up compared with a standalone CTI abla-
tion.15 Although there was a comparable recurrence rate of
AFL after CTI ablation, the recurrence rate after standalone
PVI in our study is higher than that reported by Navarrete
et al15 in their CTI plus PVI group. However, as previously
described,21,22 implantable rhythm devices in our series
allowed more detailed follow-up with identiﬁcation of even
asymptomatic arrhythmia episodes, possibly not recorded
during 48-hour Holter monitoring. In addition, we performed
complete arrhythmia monitoring without any blanking
period after the ablation procedure.
We believe that AFL is an early indicator of AF,
indicating that the PVs and most likely AF are the true
triggering mechanisms for the initiation of AFL. If AF is
indeed the underlying electrical problem, it may also explain
the comparable risk for thromboembolic events in patients
with AF and AFL.28–30 Therefore, with a higher risk of
thromboembolic complications with AFL, oral anticoagula-
tion should be considered even after successful CTI ablation
in these patients or subclinical AF must be excluded by
intensiﬁed ECG monitoring.31
This study aimed to prove the role of the PVs and the
electrophysiologic interrelationship of AFL and AF in
patients who present with AFL as their ﬁrst clinical
arrhythmia event. We want to emphasize that we do not
conclude from our results that CTI ablation is unnecessary in
case of clinical AFL. On the contrary, an important message
from this study is that even if PVI is performed in patients
with typical AFL, it is reasonable to perform CTI ablation as
well because PV reconnection is likely and patients still are
vulnerable to AFL. We agree with Navarrete et al15 that
clinicians must be aware of a strong link between AFL and
AF, indicating that CTI ablation for interruption of isolated
AFL may require additional PVI to abolish AF in order to
reduce the high thromboembolic risk, even if AF is not
clinically present.Study limitations
This is a single-center randomized study with only a limited
number of patients. Larger randomized multicenter trials
after standalone PVI are necessary to prove the need for
additional PVI in patients with AFL. All of our patients
showed ECG criteria of typical counterclockwise CVI-
dependent right AFL. Nonetheless, the diagnosis of AFL
based on 12-lead ECG may be limited, and other atrialtachycardias may have similar ECG morphologies. How-
ever, in our series a considerable portion of patients had
typical AFL at the time of the ablation procedure, which was
conﬁrmed with entrainment during the study.
There was a trend toward more induction of AF in the PVI
group. Although we carefully evaluated all documented
arrhythmia ECGs in all patients before inclusion into the
study, subclinical AF may have been present in more patients
in the PVI group but not documented before enrollment. We
cannot exclude that additional effects other than PVI
associated to left atrial debulking or effects of ganglionated
plexuses contributed to the ablation success.
One may criticize that we included a second PVI ablation
procedure in the overall outcome evaluation to prove the
effect of standalone PVI to prevent AFL. Because recurrence
rates after a single AF ablation procedure are high even at
experienced ablation centers,32,33 a second AF ablation is
often required in a relevant number of patients and should be
viewed as an integral part of PVI.Conclusion
Our data support the electrophysiologic concept that the PVs
play an important role in the initiation of AFL. AFL may be
the earliest manifestation of AF and manifests as a different
electrophysiologic manifestation because of the functional
line of block between the venae cavae. Successful PVI with
circumferential PV block seems to prevent the recurrence of
both AF and AFL.References
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In our prospective randomized study, we evaluated different treatment strategies in patients with atrial ﬂutter but without
atrial ﬁbrillation. We demonstrated that the pulmonary veins are an important trigger site for induction of atrial ﬂutter, as
already known for atrial ﬁbrillation, and that pulmonary vein isolation (PVI) can prevent atrial ﬂutter recurrences even
without cavotricuspid isthmus (CTI) ablation and in the absence of known atrial ﬁbrillation. We also showed that by using
intensiﬁed preablation continuous ECG monitoring, additional atrial ﬁbrillation can be revealed in patients with suspected
“isolated” atrial ﬂutter. With this knowledge, clinicians should be aware that after CTI ablation, the atria still are susceptible
to pulmonary vein triggers and atrial ﬁbrillation may occur. Thus, oral anticoagulation has to be continued in selected
patients. If possible, preablation screening for atrial ﬁbrillation should be considered. However, even without documented
atrial ﬁbrillation, a combined ablation procedure of CTI and PVI may be offered to patients with atrial ﬂutter to eliminate
the underlying trigger and prevent future atrial ﬁbrillation. In this way, the need for antiarrhythmic therapy, prolonged
anticoagulation treatment, or repeated ablation procedures could be spared to the patient. To obtain reliable information and
to avoid underestimation of recurrent arrhythmias after ablation procedures, continuous ECG monitoring provides a basis
for treatment decisions.
